Literature DB >> 29173772

Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.

Hong-Xia Tian1, Xu-Chao Zhang1, Jin-Ji Yang1, Wei-Bang Guo1, Zhi-Hong Chen1, Zhen Wang1, Yi-Long Wu2.   

Abstract

OBJECTIVES: To investigate the clinical characteristics of anaplastic lymphoma kinase (ALK) rearrangements and sequence complexity of the ALK fusion gene in Chinese lung cancer patients.
METHODS: We prospectively screened ALK rearrangements in 1474 lung cancer specimens, including 1387 cases of non-small cell lung cancer (NSCLC), 54 cases of small cell lung cancer (SCLC), and 33 cases of cancer with lung metastasis from other organs by both standard polymerase chain reaction (PCR) and rapid amplification of cDNA ends (RACE)-coupled PCR. Fifteen cases of ALK-positive RACE-coupled PCR products were transformed into Escherichia coli for molecular cloning and sequenced for complexity analysis.
RESULTS: The overall frequency of ALK rearrangements was 5.1% (71/1387) in NSCLC. In 71 positive cases, the coexistence of epidermal growth factor receptor (EGFR) and ALK variations was found in 6 cases (8.5%), and the coexistence of different ALK variants was found in 2 cases (2.8%) (1 case with variants 1 and 9; the other case with variants 3 and 2) by PCR analysis. Furthermore, through sequence cloning analysis of 15 cases of non-selective ALK-positive samples, two cases with variants 1 and 3 harbored the coexistence of three subtypes (variant 1 subtypes: E13; A20, E13del63; A20 and E7E12E13; A20 and variant 3 subtypes: E6; A20, E6ins33; A20 and E3E6; A20). Variant 3a and 3b subtypes were always coexistent and had the same proportion of ALK variant 3 rearrangements. ALK rearrangement was associated with young age, female gender, never-smokers, those with adenocarcinoma, advanced stage, and EGFR mutations. No ALK fusion was detected in 54 cases of SCLC or 33 cases of cancer with lung metastasis from other organs.
CONCLUSIONS: The identification of novel ALK variants, the coexistence of EGFR mutations and ALK fusions, the coexistence of ALK variants, and the coexistence of subtypes reveal the diversity and sequence complexity of ALK fusions.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALK; Diversity; EFGR; NSCLC; SCLC; Targeted molecular therapy; Variants

Mesh:

Substances:

Year:  2017        PMID: 29173772     DOI: 10.1016/j.lungcan.2017.11.001

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  8 in total

1.  ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.

Authors:  Yuanyuan Liu; Shafei Wu; Xiaohua Shi; Zhiyong Liang; Xuan Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-03       Impact factor: 4.553

2.  Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.

Authors:  Helei Hou; Chuantao Zhang; Xiaogai Qi; Lei Zhou; Dong Liu; Hongying Lv; Tianjun Li; Dantong Sun; Xiaochun Zhang
Journal:  Cancer Biol Ther       Date:  2019-10-09       Impact factor: 4.742

3.  Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC.

Authors:  Johannes Noé; Walter Bordogna; Venice Archer; Vlatka Smoljanovic; Magalie Hilton; Ryan Woodhouse; Simonetta Mocci; Shirish M Gadgeel
Journal:  JTO Clin Res Rep       Date:  2022-05-18

4.  Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers.

Authors:  De-Ning Ma; Xin-Yi Gao; Yi-Bo Dan; An-Ni Zhang; Wei-Jun Wang; Guang Yang; Hong-Zhou Zhu
Journal:  Onco Targets Ther       Date:  2020-07-16       Impact factor: 4.147

5.  Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.

Authors:  Panwen Tian; Yujie Liu; Hao Zeng; Yuan Tang; Analyn Lizaso; Junyi Ye; Lin Shao; Yalun Li
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-01       Impact factor: 4.553

6.  ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report.

Authors:  Ning Sun; Yan Zhuang; Junling Zhang; Shiqing Chen; Yuwen Dai; Renhong Guo
Journal:  Onco Targets Ther       Date:  2021-10-24       Impact factor: 4.147

7.  Development and validation of a prognosis prediction model based on 18 endoplasmic reticulum stress-related genes for patients with lung adenocarcinoma.

Authors:  Long Shu; Shuang Liu; Yongguang Tao
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

8.  Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer.

Authors:  Yuanyuan Liu; Shafei Wu; Xiaohua Shi; Linping Lu; Lingxiang Zhu; Yong Guo; Li Zhang; Xuan Zeng
Journal:  Thorac Cancer       Date:  2020-06-16       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.